Loading [MathJax]/jax/output/SVG/jax.js
Review

Mast cells, mediators, and symptomatic activation

  • Mast cells (MC) are central effectors of allergic disease and distinct subsets with varying amounts of tryptase, chymase, and carboxypeptidase A3, and cathepsin G is distributed throughout the body. Their involvement in a diverse range of non-allergic illnesses mediated by a complex range of preformed and newly synthesized mediators is now increasingly recognized. The latter especially include conditions under the umbrella term of mast cell activation syndrome. In allergic disease, much has been written about the mechanisms by which the early and rapidly acting mediators produce both localized and systemic allergic symptoms. The role of chymase is presently underappreciated but there is increased awareness that MCs contain significant amounts of preformed TNF alpha and synthesize and releases a wide range of inflammatory cytokines such as interleukins (IL) 1β, IL6, IL31, and IL33. These can aggravate itching and perpetuate inflammation and likely contribute to the late constitutional symptoms seen in allergic reactions. Importantly, their involvement helps to clarify the role of MCs in stress and non-parasitic infections. Presently, unexplained is the increasing incidence of significant acute allergic reactions within a relatively short time frame. In this context, there is increasing interest in the environmental, menstrual, endocrine, circadian, and psychological factors that influence MC activation as well as the endocrine pathways involving the renin angiotensin system that oppose hypotension. In non-allergic diseases with normal numbers of MCs, reduced thresholds for activation may be produced by various combinations of life and dietary factors. Diagnosing these conditions is difficult but may be helped by urinary analysis of prostaglandin metabolites. The investigation and management of mastocytosis with and without mutations of c-kit is also relevant to allergic disease and the new medications used may also be helpful in idiopathic anaphylaxis. This knowledge may open a new chapter in human diseases and mast cell regulation.

    Citation: Amolak S Bansal, Alex Nicholas, Nazira Sumar, Veronica Varney. Mast cells, mediators, and symptomatic activation[J]. AIMS Allergy and Immunology, 2024, 8(1): 34-55. doi: 10.3934/Allergy.2024004

    Related Papers:

    [1] Xiaoli Wang, Lizhen Wang . Traveling wave solutions of conformable time fractional Burgers type equations. AIMS Mathematics, 2021, 6(7): 7266-7284. doi: 10.3934/math.2021426
    [2] Zui-Cha Deng, Fan-Li Liu, Liu Yang . Numerical simulations for initial value inversion problem in a two-dimensional degenerate parabolic equation. AIMS Mathematics, 2021, 6(4): 3080-3104. doi: 10.3934/math.2021187
    [3] Mohammad Partohaghighi, Ali Akgül, Jihad Asad, Rania Wannan . Solving the time-fractional inverse Burger equation involving fractional Heydari-Hosseininia derivative. AIMS Mathematics, 2022, 7(9): 17403-17417. doi: 10.3934/math.2022959
    [4] M. J. Huntul . Inverse source problems for multi-parameter space-time fractional differential equations with bi-fractional Laplacian operators. AIMS Mathematics, 2024, 9(11): 32734-32756. doi: 10.3934/math.20241566
    [5] Humaira Yasmin, Aljawhara H. Almuqrin . Analytical study of time-fractional heat, diffusion, and Burger's equations using Aboodh residual power series and transform iterative methodologies. AIMS Mathematics, 2024, 9(6): 16721-16752. doi: 10.3934/math.2024811
    [6] Jian-Gen Liu, Jian Zhang . A new approximate method to the time fractional damped Burger equation. AIMS Mathematics, 2023, 8(6): 13317-13324. doi: 10.3934/math.2023674
    [7] Farman Ali Shah, Kamran, Zareen A Khan, Fatima Azmi, Nabil Mlaiki . A hybrid collocation method for the approximation of 2D time fractional diffusion-wave equation. AIMS Mathematics, 2024, 9(10): 27122-27149. doi: 10.3934/math.20241319
    [8] Asif Khan, Tayyaba Akram, Arshad Khan, Shabir Ahmad, Kamsing Nonlaopon . Investigation of time fractional nonlinear KdV-Burgers equation under fractional operators with nonsingular kernels. AIMS Mathematics, 2023, 8(1): 1251-1268. doi: 10.3934/math.2023063
    [9] Xiangtuan Xiong, Wanxia Shi, Xuemin Xue . Determination of three parameters in a time-space fractional diffusion equation. AIMS Mathematics, 2021, 6(6): 5909-5923. doi: 10.3934/math.2021350
    [10] Shuang-Shuang Zhou, Saima Rashid, Asia Rauf, Khadija Tul Kubra, Abdullah M. Alsharif . Initial boundary value problems for a multi-term time fractional diffusion equation with generalized fractional derivatives in time. AIMS Mathematics, 2021, 6(11): 12114-12132. doi: 10.3934/math.2021703
  • Mast cells (MC) are central effectors of allergic disease and distinct subsets with varying amounts of tryptase, chymase, and carboxypeptidase A3, and cathepsin G is distributed throughout the body. Their involvement in a diverse range of non-allergic illnesses mediated by a complex range of preformed and newly synthesized mediators is now increasingly recognized. The latter especially include conditions under the umbrella term of mast cell activation syndrome. In allergic disease, much has been written about the mechanisms by which the early and rapidly acting mediators produce both localized and systemic allergic symptoms. The role of chymase is presently underappreciated but there is increased awareness that MCs contain significant amounts of preformed TNF alpha and synthesize and releases a wide range of inflammatory cytokines such as interleukins (IL) 1β, IL6, IL31, and IL33. These can aggravate itching and perpetuate inflammation and likely contribute to the late constitutional symptoms seen in allergic reactions. Importantly, their involvement helps to clarify the role of MCs in stress and non-parasitic infections. Presently, unexplained is the increasing incidence of significant acute allergic reactions within a relatively short time frame. In this context, there is increasing interest in the environmental, menstrual, endocrine, circadian, and psychological factors that influence MC activation as well as the endocrine pathways involving the renin angiotensin system that oppose hypotension. In non-allergic diseases with normal numbers of MCs, reduced thresholds for activation may be produced by various combinations of life and dietary factors. Diagnosing these conditions is difficult but may be helped by urinary analysis of prostaglandin metabolites. The investigation and management of mastocytosis with and without mutations of c-kit is also relevant to allergic disease and the new medications used may also be helpful in idiopathic anaphylaxis. This knowledge may open a new chapter in human diseases and mast cell regulation.


    Abbreviations

    ACE:

    angiotensin converting enzyme; 

    RAS:

    renin angiotensin system; 

    AII:

    angiotensin-2; 

    AI:

    angiotensin-1; 

    PAF:

    platelet activating factor; 

    eNO:

    endothelial nitric oxide; 

    ATR-1:

    angiotensin-2 receptor; 

    BK:

    bradykinin; 

    BP:

    blood pressure; 

    C5a:

    complement protein C5a; 

    C3a:

    complement protein C3a; 

    mRNA:

    messenger RNA; 

    IgE:

    Immunoglobulin E

    In recent years, fractional partial differential equations (FPDEs) have been widely used in natural science and engineering technology [1,2,3,4]. The advantage of FPDEs lies in their ability to better describe materials and processes that exhibit memory and genetic properties [5,6]. However, the solutions of FPDEs are much more complex. Many researchers have exploited diverse techniques for the investigation of FPDEs such as the finite difference method (FDM) [7], finite element method [8], spectral method [9], virtual element method [10], etc. The development of effective numerical methods to approximate FPDEs has been the goal of some researchers.

    In recent years, neural networks (NNs) have been successfully applied to solve problems in various fields [11,12,13]. Due to the high expressiveness of NNs in functional approximation [14,15,16], using NNs to solve differential and integral equations has become an active and important research field. Physics-informed neural networks (PINNs) [17,18,19,20] are machine learning models that combine deep learning with physical knowledge. PINNs embed PDEs into the loss function of the NNs, enabling the NNs to learn solutions to PDEs. The PINNs algorithm is meshless and simple, and can be applied to various types of PDEs, including integral differential equations, FPDEs, and random partial differential equations. Moreover, PINNs solved the inverse problem of PDEs just as easily as they solved the forward problem [17]. PINNs have been successfully applied to solve various problems in scientific computing [21,22,23]. Pang et al. [24] used the FDM to approximate the fractional derivatives that cannot be automatically differentiated, thus extending the PINNs to fPINNs for solving FPDEs.

    Despite the success of deep learning in the past, solving a wide range of PDEs is theoretically and practically challenging as complexity increases. Therefore, many aspects of PINNs need to be further improved to achieve more accurate predictions, higher computational efficiency, and robustness of training. Lu et al. [25] proposed DeepXDE, a deep learning library for solving PDEs, introduced a new residual-based adaptive refinement method to improve the training efficiency of PINNs, and new residual points were added at the position where the residuals of the PDEs were large, so that the discontinuities of PDEs could be captured well. Zhang et al. [26] combined fPINNs with the spectral method to solve the time-fractional phase field models. It had the characteristics of reducing the approximate number of discrete fractional operators, thus improving the training efficiency and obtaining higher error accuracy. Wu et al. [27] conducted a comprehensive study on two types of sampling of PINNs, including non-adaptive uniform sampling and adaptive non-uniform sampling, and the research results could also be used as a practical guide for selecting sampling methods. Zhang et al. [28] removed the soft constraints of PDEs in the loss function, and used the Lie symmetry group to generate the labeled data of PDEs to build a supervised learning model, thus effectively predicting the large amplitude and high frequency solutions of the Klein-Gordon equation. Zhang et al. [29] introduced the symmetry-enhanced physics-informed neural network (SPINN), which incorporated the invariant surface conditions derived from Lie symmetries or non-classical symmetries of PDEs into the loss function of PINNs, aiming to improve accuracy of PINNs. Lu et al. [30] and Xie et al. [31] introduced gradient-enhanced physics-informed neural networks (gPINNs) to solve PDEs and the idea of embedding the gradient information from the residuals of PDEs into the loss functions has also proven to be effective in other methods such as Gaussian process regression [32].

    In this paper, inspired by the above works, gfPINNs are applied to solve the forward and inverse problems of the multiterm time-fractional Burger-type equation. The integer order derivatives are handled using the automatic differentiation capability of the NNs, while the fractional derivatives of the equation are approximated using finite difference discretization [33,34]. Subsequently, the residual information of the equation is then incorporated into the loss function of NNs and optimized to yield optimal parameters. For the inverse problems of the multiterm time-fractional Burger-type equation, their overall form are known but the coefficient and the orders of time-fractional derivatives are unknown. The gfPINNs explicitly incorporate information from the equation by including the differential operators of the equation directly into the optimization loss function. The parameters to be identified appear in the differential operators, which are then optimized by minimizing the loss function associated with those parameters. A numerical comparison between fPINNs and gfPINNs is conducted using numerical examples. The numerical results demonstrate the effectiveness of gfPINNs in solving the multiterm time-fractional Burger-type equation.

    The structure of this paper is as follows. In Section 2, we define forward and inverse problems for the multiterm time-fractional Burger-type equation. In Section 3, we introduce fPINNs and gfPINNs and give the finite difference discretization to approximate the time-fractional derivatives. In Section 4, we demonstrate the effectiveness of gfPINNs in solving the forward and inverse problems of the multiterm time-fractional Burger-type equation by numerical examples, and compare the experimental results of fPINNs and gfPINNs. Finally, we give the conclusions of this paper in Section 5.

    We consider the following multiterm time-fractional Burger-type equation defined on the bounded domain Ω:

    c1C0Dαtu(x,t)+c2C0Dγtu(x,t)+u(x,t)u(x,t)x=v2u(x,t)x2+f(x,t), (2.1)

    where (x,t)Ω×[0,T] and the initial and boundary conditions are given as

    {u(x,t)=0,xΩ,u(x,0)=g(x),xΩ, (2.2)

    where u(x,t) is the solution of the equation, f(x,t) is the forcing term whose values are only known at scattered spatio-temporal coordinates, v is the kinematic viscosity of fluid, g(x) is a sufficiently smooth function, the fractional orders α and γ have been restricted to (0, 1) and (1, 2), respectively, C0Dθtu(x,t) is the Caputo time-fractional derivative of order θ (θ>0,n1θ<n) of u(x,t) with respect to t [35,36]:

    C0Dθtu(x,t)={1Γ(nθ)tα(ts)n1θnu(x,s)snds,θz+,θu(x,t)tθ,θz+, (2.3)

    where Γ() is the gamma function.

    The forward and inverse problems of solving the multiterm time-fractional Burger-type equation are described as follows. For the forward problem, under the given preconditions of the fractional orders α and γ, the forcing term f, and the initial and boundary conditions, the solution u(x,t) is solved. For the inverse problem, under the given preconditions of the initial and boundary conditions, the forcing term f, and additional concentration measurements at the final time u(x,t)=h(x,t), the fractional orders α and γ, the flow velocity v, and the solution u(x,t) are solved.

    This subsection introduces the idea of fPINNs and we consider both the forward and inverse problems, along with their corresponding NNs. We first consider the forward problem of the multiterm time-fractional Burger-type equation in the following form:

    {L{u(x,t)}=f(x,t),(x,t)Ω×[0,T],u(x,t)=0,xΩ,u(x,0)=g(x),xΩ, (3.1)

    where L{} is a nonlinear operator and L{u(x,t)}=c1C0Dαtu(x,t)+c2C0Dγtu(x,t)+u(x,t)u(x,t)xv2u(x,t)x2. We divide the nonlinear operator L{} into two parts, L=LAD+LnonAD. The first part is an integer derivative operator, which can be automatically differentiated (AD) using the chain rule. We have

    LAD{}={u(x,t)u(x,t)xv2u(x,t)x2,α(0,1),γ(1,2),c22u(x,t)t2+u(x,t)u(x,t)xv2u(x,t)x2,α(0,1),γ=2,c1u(x,t)t+u(x,t)u(x,t)xv2u(x,t)x2,α=1,γ(1,2), (3.2)

    and the second category consists of operators that lack automatic differentiation capabilities:

    LnonAD{}={c1C0Dαtu(x,t)+c2C0Dγtu(x,t),α(0,1),γ(1,2),c1C0Dαtu(x,t),α(0,1),γ=2,c2C0Dγtu(x,t),α=1,γ(1,2). (3.3)

    For LnonAD, we can discretize it using FDM and denote by LFDM the discretization version of LnonAD.

    During the NNs training process, our goal is to optimize its parameters in order to ensure that the approximate solution of the equation closely satisfies the initial and boundary conditions. The approximate solution is chosen as

    ˜u(x,t)=tρ(x)uNN(x,t)+g(x), (3.4)

    where uNN represents the output of the NNs. The NNs acts as a surrogate model, approximating the relationship between spatio-temporal coordinates and the solution of the equation. It is defined by its weights and biases, forming the parameter vector μ; see Figure 1 for a simple NN. This is fully connected with a single hidden layer consisting of three neurons. In this network, x and t are two inputs, which go through a linear transformation to obtain x1=w1x+w4t+b1, x2=w2x+w5t+b2, and x3=w3x+w6t+b3 in the hidden layer, and then, they go through a nonlinear transformation to get Yi=f(xi) for i=1,2,3. We choose the hyperbolic tangent function tanh(). Yi to go through a linear transformation to obtain the output of the NNs, uNN(x,t;μ)=w7Y1+w8Y2+w9Y3+b4. The vector of parameters μ is comprised of the weights wi and biases bi. ρ(0)=ρ(1)=0 and the auxiliary function ρ(x) is preselected. g(x) is the initial condition function such that it satisfies the initial and boundary conditions automatically.

    Figure 1.  A simple NN.

    The loss function of fPINNs for the forward problem with the approximate solution is defined as the mean-squared error of the equation residual

    LFW=1|SF|(x,t)S[LFDM{˜u(x,t)}+LAD{˜u(x,t)}f(x,t)]2, (3.5)

    where SFΩ×[0,T] and |SF| represents the number of training points. Then, we train the NNs to optimize the loss function of the forward problem with respect to the NNs parameters μ, thus obtaining the optimal parameters μbest. Finally, we specify a set of arbitrary test points to test the trained NNs and observe the training performance.

    The codes for solving the forward and inverse problems of the equation using NNs is similar. We only need to incorporate the parameters to be identified in the inverse problem into the loss function to be optimized in the forward problem, and no other changes are necessary. Next, we consider the following form of the inverse problem:

    {Lξ={α,γ,v}{u(x,t)}=f(x,t),(x,t)Ω×[0,T],u(x,t)=0,xΩ,u(x,0)=g(x),xΩ,u(x,t)=h(x,t),(x,t)Ω×[0,T], (3.6)

    where ξ is the parameter of the equation, so the loss function LIV for the inverse problem under consideration is

    LIV{μ,ξ={α,γ,v}}=WI11|SI1|(x,t)SI1[L{α,γ}FDM{˜u(x,t)}+LvAD{˜u(x,t)}f(x,t)]2+WI21|SI2|(x,t)SI2[˜u(x,t)h(x,t)]2, (3.7)

    where α(0,1) and γ(1,2), SI1Ω×[0,T] and SI2Ω×[0,T] are two sets of different training points, and WI1 and WI2 are preselected weight coefficients. We train the NNs to minimize the loss function, thereby obtaining αbest and γbest, the flow velocity vbest, and the optimal parameters μbest of the NNs.

    We incorporate the residual information of the equation into the loss function of NNs and train the NNs to minimize this loss function, thus obtaining the optimal parameters of NNs. If the residuals in the PDEs are zero, then the gradient of the residuals in the PDEs should also be zero. Therefore, adding gradient information to the loss function is a necessary condition for training NNs. One motivation behind gfPINNs is that the residual in the loss function often fluctuates near zero. Penalizing the slope of the residual can reduce these fluctuations, making the residual closer to zero. In this section, we continue to consider the formulation of the forward and inverse problems of the equation discussed in the previous section.

    We first consider the forward problem in the form of (3.1) and provide the loss function of gfPINNs for this form:

    LgFW=WFLFW+Wg1FLg1FW+Wg2FLg2FW, (3.8)

    where

    Lg1FW=1|Sg1F|(x,t)Sg1F[LFDM{˜u(x,t)}x+LAD{˜u(x,t)}xf(x,t)x]2, (3.9)
    Lg2FW=1|Sg2F|(x,t)Sg2F[LFDM{˜u(x,t)}t+LAD{˜u(x,t)}tf(x,t)t]2, (3.10)

    and the approximate solution of the equation is the same as Eq (3.4): ˜u(x,t)=ρ(x)uNN(x,t)+g(x). The expression LFW as shown in Eq (3.5), where WF, Wg1F, and Wg2F are preselected weighting coefficients, Sg1FΩ×[0,T] and Sg2FΩ×[0,T] are two sets of different training points.

    Next, we consider the inverse problem in the form of (3.6) and provide the loss function of gfPINNs for this form. The approach for the inverse problem of gfPINNs is similar to that of fPINNs. We provide the loss function for the inverse problem of gfPINNs.

    LgIV=WILIV{μ,ξ={α,γ,v}}+Wg1ILg1IV+Wg2ILg2IV, (3.11)

    where

    Lg1IV=Wg1I11|Sg1I1|(x,t)Sg1I1[L{α,γ}FDM{˜u(x,t)}x+LvAD{˜u(x,t)}xf(x,t)x]2+Wg1I21|Sg1I2|(x,t)Sg1I2[˜u(x,t)xh(x,t)x]2, (3.12)
    Lg2IV=Wg2I11|Sg2I1|(x,t)Sg2I1[L{α,γ}FDM{˜u(x,t)}t+LvAD{˜u(x,t)}tf(x,t)t]2+Wg2I21|Sg2I2|(x,t)Sg2I2[˜u(x,t)th(x,t)t]2, (3.13)

    and the expression LIV{μ,ξ={α,γ,v}} as shown in Eq (3.7), where WI, Wg1I, Wg2I, Wg1I1, Wg1I2, Wg2I1, and Wg2I2 are preselected weighting coefficients, Sg1I1,Sg2I1Ω×[0,T], Sg1I2,andSg2I2Ω×[0,T] are four sets of different training points.

    This defines the loss function of gfPINNs, which is exactly the same as discussed above for fPINNs. We train the NNs to obtain the optimal parameters of the NNs.

    In the x direction [0,M], we take the mesh points xp=ihx,i=0,1,2,...,M1, and in the t direction [0,T], we take the mesh points tn=nτ,n=0,1,...,N, where hx=MM1 and τ=TN are the uniform spatial step size and temporal step size, respectively. Denote Ωh{0iM1}, Ωτ{0nN}. Suppose uni = u(xi,tn) is a grid function on Ωh×Ωτ.

    We approximate the fractional derivatives of the equation using the finite difference discretization [33,34].

    For α(0,1), we have C0Dαtu(x,t)(xi,tn)=Dατ˜uni+R1(˜uni),

    Dατ˜uni:=ταΓ(2α)[aα0˜uni+n1k=1(aαnkaαnk1)˜ukiaαn1˜u0i], (3.14)

    where ˜uni=˜u(xi,tn), R1C(τ2α), and aαk=(k+1)1αk1α.

    Lemma 3.1. [33] α(0,1), aαl=(l+1)1αl1α, l=0,1,2,,

    (1) 1=aα0>aα1>aα2>>aαl>0,limlaαl0,

    (2) (1α)lα<a(α)l1<(1α)(l1)α,l1.

    For γ(1,2), C0Dγtu(x,t)(xi,tn)=Dγτ˜uni+R2(˜uni),

    Dγτ˜uni:=τ1γΓ(3γ)[bγ0δt˜uni+n1k=1(bγnkbγnk1)δt˜ukibγn1δt˜u0i], (3.15)

    where δtu(x,t)=u(x,t)t, R2C(τ3γ), and bγk=(k+1)2γk2γ.

    Given the spatial position x, it can be seen from the finite difference discretization that the time-fractional derivative of ˜u(x,t) evaluated at time t depends on the value of ˜u(x,t) calculated at all previous times 0, τ, 2τ, , t. We call the current time and the previous time the training points and the auxiliary points, respectively.

    In this section, we demonstrate the effectiveness of gfPINNs in solving forward and inverse problems of the multiterm time-fractional Burger-type equation and we compared fPINNs with gfPINNs. We solve the forward problems of the equation and present the experimental results in Section 4.1. We solve the inverse problems and present the experimental results in Section 4.2.

    We give a fabricated solution to the problem u(x,t)=tpsin(πx). In the given approximate solution (3.4), the auxiliary function ρ() is defined as ρ()=1x22. We use the following form of L2 relative error:

    {k[u(xtest,k,ttest,k)˜u(xtest,k,ttest,k)]2}12{k[u(xtest,k,ttest,k)]2}12 (4.1)

    to measure the performance of the NNs, where ˜u denotes the approximated solution, u is the exact solution, and (xk,tk) denotes the k-th test point.

    We wrote the code in Python and took advantage of the automatic differentiation capability of TensorFlow [37]. The stochastic gradient descent Adam algorithm [38] was used to optimize the loss function. We initialized the NNs parameters using normalized Glorot initialization [39]. Otherwise, when training a neural network, we set the learning rate, the number of neurons, the number of hidden layers, and the activation function as 1×103, 20, 4, and tanh(x), respectively.

    In this section, we consider the the multiterm time-fractional Burger-type equation of the form (2.1) with initial and boundary conditions (2.2). We let v=1, (x,t)[0,1]×[0,1], and g(x)=0, considering the smooth fabricated solution u(x,t)=tpsin(πx) and the forcing term

    f(x,t)=Γ(p+1)Γ(p+1α)t(pα)(pα)sin(πx)+Γ(p+1)Γ(p+1γ)t(pγ)(pγ)sin(πx)+t2psin(πx)cos(πx)+π2tpsin(πx). (4.2)

    Case 1: We choose c1=1, c2=0, and α=0.5, considering the smooth fabricated solution u(x,t)=t4sin(πx) and the forcing term f(x,t)=3.5Γ(5)Γ(4.5)t3.5sin(πx)+t8sin(πx)cos(πx)+π2t4sin(πx). We consider M11 training points of the spatial domain: xi=ihx for i=1,2,,M11 and N training points of the time domain: tn=nτ for n=1,2,,N. We do not need to place training points on the initial and boundary since the approximate solution ˜u(x,t)=tx(1x)uNN(x,t;μ) satisfies the initial and boundary conditions automatically. For fPINNs, the loss function can be written as

    LFW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[a0.50˜u(xi,tn)+n1k=1(a0.5nka0.5nk1)˜u(xi,tk)]+˜u(xi,tn)˜u(xi,tn)xi2˜u(xi,tn)x2if(xi,tn)}2. (4.3)

    The loss function of gfPINNs can be given as

    Lg2FW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[a0.50˜u(xi,tn)xi+n1k=1(a0.5nka0.5nk1)˜u(xi,tk)xi]+˜u(xi,tn)2˜u(xi,tn)x2i+(˜u(xi,tn)xi)23˜u(xi,tn)x3if(xi,tn)xi}2, (4.4)
    Lg2FW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[a0.50˜u(xi,tn)tn+n1k=1(a0.5nka0.5nk1)˜u(xi,tk)tk]+˜u(xi,tn)2˜u(xi,tn)xitn+˜u(xi,tn)xi˜u(xi,tn)tn3˜u(xi,tn)x2itnf(xi,tn)tn}2. (4.5)

    By substituting Eqs (4.3)–(4.5) into Eq (3.8), we get the gfPINNs loss function LgFW with WF=1, Wg1F=1, and Wg2F=1. Next, we selected 2000 training points to train fPINNs and gfPINNs and other parameters of the NNs are set to those described at the beginning of this section. Figures 24 present a comparison between the predicted solutions from the fPINNs and gfPINNs models and the exact solution of the equation, demonstrating that gfPINNs can effectively solve the equation. Figure 5 shows the absolute errors between the exact solution and the solutions predicted by fPINNs and gfPINNs, and it can be seen that the prediction performance of gfPINNs is better than that of fPINNs. Figure 6 illustrates the L2 relative errors of both fPINNs and gfPINNs models for a single experiment as the iteration count varies, showing that while both can achieve errors as low as 104, gfPINNs exhibits comparatively lower error and reduced oscillation.

    Figure 2.  The exact solution and predicted solutions of the equation.
    Figure 3.  The exact solution and numerical solutions' profiles of velocity u(x,t) with α=0.5.
    Figure 4.  Predicted cross-sectional views of the equation using fPINNs and gfPINNs.
    Figure 5.  The absolute errors for solutions predicted by fPINNs and gfPINNs.
    Figure 6.  The L2 relative error of the problem with the number of iterations.

    Case 2: We choose c1=0, c2=1, and γ=1.5, considering the smooth fabricated solution u(x,t)=t4sin(πx) and the forcing term f(x,t)=2.5Γ(5)Γ(3.5)t2.5sin(πx)+t8sin(πx)cos(πx)+π2t4sin(πx). Similarly, we give the loss function of fPINNs as

    LFW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[b1.50˜u(xi,tn)tn+n1k=1(b1.5nkb1.5nk1)˜u(xi,tn)tk]+˜u(xi,tn)˜u(xi,tn)xi2˜u(xi,tn)x2if(xi,tn)}2. (4.6)

    For gfPINNs, the loss function can be written as

    Lg1FW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[b1.502˜u(xi,tn)tnxi+n1k=1(b1.5nkb1.5nk1)2˜u(xi,tk)tkxi]+˜u(xi,tn)2˜u(xi,tn)x2i+(˜u(xi,tn)xi)23˜u(xi,tn)x3if(xi,tn)xi}2, (4.7)
    Lg2FW=1(M11)NM1i=1Nn=1{τ0.5Γ(1.5)[b1.502˜u(xi,tn)t2n+n1k=1(b1.5nkb1.5nk1)2˜u(xi,tk)t2k]+˜u(xi,tn)2˜u(xi,tn)xitn+˜u(xi,tn)xi˜u(xi,tn)tn3˜u(xi,tn)x2itnf(xi,tn)tn}2. (4.8)

    By substituting Eqs (4.6)–(4.8) into Eq (3.8), we get the gfPINNs loss function LgFW with WF=1, Wg1F=0.16, and Wg2F=0.16. Next, we selected 2000 training points to train fPINNs and gfPINNs and other parameters of the NNs are set to those described at the beginning of this section. Figures 79 present a comparison between the predicted solutions from the fPINNs and gfPINNs models and the exact solution of the equation, demonstrating that gfPINNs can effectively solve the equation. Figure 10 illustrates the absolute errors between the exact solution and the solutions predicted by both fPINNs and gfPINNs, revealing that the gfPINNs exhibit a relatively smaller absolute error. Figure 11 presents the iteration convergence curves for both the fPINNs and gfPINNs models for a single experiment, revealing that while both can achieve L2 relative errors of 104 with increasing iterations, the prediction errors of gfPINNs are relatively low and more stable, resulting in superior prediction performance compared to fPINNs.

    Figure 7.  The exact solution and predicted solutions of the equation.
    Figure 8.  The exact solution and numerical solutions' profiles of velocity u(x,t) with γ=1.5.
    Figure 9.  Predicted cross-sectional views of the equation using fPINNs and gfPINNs.
    Figure 10.  The absolute errors for solutions predicted by fPINNs and gfPINNs.
    Figure 11.  The L2 relative error of the problem with the number of iterations.

    We use the code that solves the forward problem to solve the inverse problem. We simply add the parameters to be identified in the inverse problem to the list of parameters to be optimized in the forward problem, without changing anything else. In this section, gfPINNs are applied to solve the inverse problems of the multiterm time-fractional Burger-type equation of the form (3.6). We let v=1, (x,t)[0,1]×[0,1], g(x)=0, and considering additional concentration measurements at the final time u(x,1)=h(x,1). Here, we still consider the smooth fabricated solution u(x,t)=tpsin(πx) and the forcing term of formula (4.2).

    Case 1: We choose c1=1 and c2=0. Similarly, we get the gfPINNs loss function LgFW with WI=1, Wg1I=0.25, and Wg2I=0.25. We set the fractional derivative to be 0.6. We selected 470 training points to train fPINNs and gfPINNs and other parameters of the NNs are set to those described at the beginning of this section. Figures 1214 display a comparison between the predicted solutions from the fPINNs and gfPINNs models and the exact solution of the equation, demonstrating that gfPINNs can effectively solve the problem. Figure 15 illustrates the absolute errors between the exact solution and the solutions predicted by both fPINNs and gfPINNs, revealing that the gfPINNs exhibit a relatively smaller and more stable absolute error. Figure 16 illustrates the iteration convergence curves for the fPINNs and gfPINNs for a single experiment, indicating that although gfPINNs incur a higher computational cost for solving the inverse problem due to an additional loss term, both models can achieve L2 relative errors of 104 as iterations progress, with gfPINNs showing a lower and more stable error curve compared to fPINNs.

    Figure 12.  The exact solution and predicted solutions of the equation.
    Figure 13.  The exact solution and numerical solutions' profiles of velocity u(x,t).
    Figure 14.  Predicted cross-sectional views of the equation using fPINNs and gfPINNs.
    Figure 15.  The absolute errors for solutions predicted by fPINNs and gfPINNs.
    Figure 16.  The L2 relative error of the problem with the number of iterations.

    Case 2: We choose c1=0 and c2=1. Similarly, we get the gfPINNs loss function LgFW with WI=1, Wg1I=0.16, and Wg2I=0.0001. We set the fractional derivative to be 1.6. We selected 400 training points to train fPINNs and gfPINNs and other parameters of the NNs are set to those described at the beginning of this section. For fPINNs and gfPINNs, we get the similar conclusion as Case 1 by training the NNs and observing the experimental results. Figures 1719 display a comparison between the predicted solutions from the fPINNs and gfPINNs models and the exact solution of the equation, demonstrating that gfPINNs can effectively solve the problem. Figure 20 illustrates the absolute errors between the exact solution and the solutions predicted by both fPINNs and gfPINNs, revealing that the gfPINNs exhibit a relatively smaller absolute error. Figure 21 compares the L2 relative errors of fPINNs and gfPINNs for a single experiment as iterations progress, revealing that while gfPINNs incurs a higher computational cost due to an additional loss term, both models can achieve an L2 relative error of 103, with gfPINNs demonstrating a lower and more stable error curve than fPINNs.

    Figure 17.  The exact solution and predicted solutions of the equation.
    Figure 18.  The exact solution and numerical solutions' profiles of velocity u(x,t).
    Figure 19.  Predicted cross-sectional views of the equation using fPINNs and gfPINNs.
    Figure 20.  The absolute errors for solutions predicted by fPINNs and gfPINNs.
    Figure 21.  The L2 relative error of the problem with the number of iterations.

    In this paper, the effectiveness of gfPINNs in solving the forward and inverse problems of the multiterm time-fractional Burger-type equation is verified through numerical examples. The L2 relative errors for solutions predicted by both fPINNs and gfPINNs can achieve 104 for forward problems and 103 or even 104 for inverse problems. The experimental results indicate that gfPINNs demonstrate relatively lower and more stable errors with the increase of training iterations, thereby enhancing prediction performance. Nonetheless, the inclusion of an additional loss term in gfPINNs may result in a higher computational cost, such as when solving inverse problems, fPINNs exhibit faster convergence compared to gfPINNs.

    Shanhao Yuan, Yanqin Liu, Qiuping Li and Chao Guo: Conceptualization, Methodology; Yibin Xu, Shanhao Yuan and Yanfeng Shen: Software, Visualization, Validation; Shanhao Yuan: Writing–Original draft preparation; Yanqin Liu: Writing–Reviewing & editing. All authors have read and approved the final version of the manuscript for publication.

    We appreciated the support by the Natural Science Foundation of Shandong Province (ZR2023MA062), the National Science Foundation of China (62103079), the Belt and Road Special Foundation of The National Key Laboratory of Water Disaster Prevention (2023491911), and the Open Research Fund Program of the Data Recovery Key Laboratory of Sichuan Province (DRN19020).

    The authors declare that they have no conflicts of interest.



    Conflict of interest



    All authors declare no conflicts of interest in this paper.

    [1] Bjornsson HM, Graffeo CS (2010) Improving diagnostic accuracy of anaphylaxis in acute care setting. West J Emerg Med 11: 456-461.
    [2] Tejeclor A, Lonson MA, Moromoro M, et al. (2014) Epidemiology of anaphylaxis. Clin Exp Allergy 45: 1027-1039. https://doi.org/10.1111/cea.12418
    [3] Mullins RJ, Wainstein BK, Barnes EH, et al. (2016) Increases in anaphylaxis fatalities in Australia from 1997–2013. Clin Exp Allergy 46: 1099-1110. https://doi.org/10.1111/cea.12748
    [4] Sheikh A, Alves B (2001) Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clin Exp All 31: 1571-1576. https://doi.org/10.1046/j.1365-2222.2001.01203.x
    [5] Braganza SC, Acworth JP, McKinnon DRL, et al. (2006) Paediatric emergency department anaphylaxis: different patterns from Adults. Arch Dis Child 91: 159-163. https://doi.org/10.1136/adc.2004.069914
    [6] Macdougall CF, Cart AJ, Clover AF (2002) How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across UK and Ireland. Arch Dis Child 86: 236-237. https://doi.org/10.1136/adc.86.4.236
    [7] Vetander M, Protudjer JLP, Liija G, et al. (2016) Anaphylaxis to foods in a population of adolescents: incidence, characteristics and associated risks. Clin Exp Allergy 46: 1575-1587. https://doi.org/10.1111/cea.12842
    [8] Terr AI (1985) Anaphylaxis. Clin Rev Allergy 3: 3-23. https://doi.org/10.1007/BF02993040
    [9] Delage C, Irey NS (1972) Anaphylactic deaths: a Clinicopathologic study of 43 cases. J Forensic Sci 17: 525-540. https://doi.org/10.1520/JFS10141J
    [10] Greenberger PA, Rotskoff BD, Lifschultz B (2007) Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 98: 252-257. https://doi.org/10.1016/S1081-1206(10)60714-4
    [11] Smith PK, Hourihane JO, Lieberman P (2005) Risk multipliers for severe food anaphylaxis. World Allergy Organ J 8: 30. https://doi.org/10.1186/s40413-015-0081-0
    [12] Pumphrey R, Stanworth SJ (1996) The clinical spectrum of anaphylaxis in north-west England. Clin Exp All 26: 1364-1370. https://doi.org/10.1111/j.1365-2222.1996.tb00537.x
    [13] Pumphrey RS (2000) Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 30: 1144-1150. https://doi.org/10.1046/j.1365-2222.2000.00864.x
    [14] Reber LL, Hernandez JD, Galli SJ (2007) The pathophysiology of anaphylaxis. J Allergy Clin Immunol 140: 335-348. https://doi.org/10.1016/j.jaci.2017.06.003
    [15] Gupta R, Sheikh A, Strachan DP (2007) Time trends in allergic disorders in the UK. Thorax 62: 91-96. https://doi.org/10.1136/thx.2004.038844
    [16] Berlin MC (2015) Pathogenesis of IgE mediated food allergy. Clin Exp Allergy 45: 1483-1496. https://doi.org/10.1111/cea.12598
    [17] Harper NJN, Cook TM, Garcez T, et al. (2018) Anaesthesia, surgery and life-threatening allergic reactions: Management and outcomes in the 6th National Audit Project (NAP6). Br J Anaesth 121: 159-171. https://doi.org/10.1016/j.bja.2018.04.015
    [18] Sato T, Morishita S, Horie T, et al. (2019) Involvement of premacular mast cells in the pathogenesis of macular diseases. PLoS One 14: e0211438. https://doi.org/10.1371/journal.pone.0211438
    [19] Lauritano D, Mastrangelo F, D'Ovidio C, et al. (2023) Activation of mast cells by neuropeptides: The role of pro-inflammatory and anti-inflammatory cytokines. Int J Mol Sci 24: 4811. https://doi.org/10.3390/ijms24054811
    [20] Nishino S, Sakai N, Nishino N, et al. (2022) Brain mast cells in sleep and behavioral regulation. Curr Top Behav Neurosci 59: 427-446. https://doi.org/10.1007/7854_2022_359
    [21] Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373: 163-172. https://doi.org/10.1056/NEJMra1409760
    [22] Leguit RJ, Wang SA, George TI, et al. (2023) The international consensus classification of mastocytosis and related entities. Virchows Arch 482: 99-112. https://doi.org/10.1007/s00428-022-03423-3
    [23] Gülen T, Akin C, Bonadonna P, et al. (2021) Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: A critical review. J Allergy Clin Immunol Pract 9: 3918-3928. https://doi.org/10.1016/j.jaip.2021.06.011
    [24] Valent P, Hartmann K, Bonadonna P, et al. (2022) Mast cell activation syndromes: Collegium internationale allergologicum update. Int Arch Allergy Immunol 183: 693-705. https://doi.org/10.1159/000524532
    [25] Hellman L, Akula S, Fu Z, et al. (2022) Mast cell and basophil granule proteases - In Vivo targets and function. Front Immunol 13: 918305. https://doi.org/10.3389/fimmu.2022.918305
    [26] Bian G, Gu Y, Xu C, et al. (2021) Early development and functional properties of tryptase/chymase double-positive mast cells from human pluripotent stem cells. J Mol Cell Biol 13: 104-115. https://doi.org/10.1093/jmcb/mjaa059
    [27] Komi DEA, Rambasek T, Wöhrl S (2018) Mastocytosis: From a molecular point of view. Clin Rev Allergy Immunol 54: 397-411. https://doi.org/10.1007/s12016-017-8619-2
    [28] Irani AA, Schechter NM, Craig SS, et al. (1986) Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 83: 4464-4468. https://doi.org/10.1073/pnas.83.12.4464
    [29] Siddhuraj P, Clausson CM, Sanden C, et al. (2021) Lung mast cells have a high constitutive expression of carboxypeptidase A3 mRNA that is independent from granule-stored CPA3. Cells 10: 309. https://doi.org/10.3390/cells10020309
    [30] Donelan J, Boucher W, Papadopoulou N, et al. (2006) Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 103: 7759-7764. https://doi.org/10.1073/pnas.0602210103
    [31] Mustain WC, Rychahou PG, Evers BM (2011) The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes 18: 75-82. https://doi.org/10.1097/MED.0b013e3283419052
    [32] Gaudenzio N, Sibilano R, Marichal T, et al. (2016) Different activation signals induce distinct mast cell degranulation strategies. J Clin Invest 126: 3981-3998. https://doi.org/10.1172/JCI85538
    [33] Cianferoni A (2021) Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol 147: 1123-1131. https://doi.org/10.1016/j.jaci.2021.02.012
    [34] Poto R, Quinti I, Marone G, et al. (2022) IgG autoantibodies against IgE from atopic dermatitis can induce the release of cytokines and proinflammatory mediators from basophils and mast cells. Front Immunol 13: 880412. https://doi.org/10.3389/fimmu.2022.880412
    [35] Wernersson S, Pejler G (2014) Mast cell secretory granules: armed for battle. Nat Rev Immunol 14: 478-494. https://doi.org/10.1038/nri3690
    [36] Lee J, Vadas P (2011) Anaphylaxis: mechanisms and management. Clin Exp Allergy 41: 923-938. https://doi.org/10.1111/j.1365-2222.2011.03779.x
    [37] Lundequist A, Pejler G (2011) Biological implications of preformed mast cell mediators. Cell Mol Life Sci 68: 965-975. https://doi.org/10.1007/s00018-010-0587-0
    [38] Theoharides TC, Kempuraj D, Tagen M, et al. (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217: 65-78. https://doi.org/10.1111/j.1600-065X.2007.00519.x
    [39] Morita H, Nakae S, Saito H, et al. (2017) IL-33 in clinical practice: Size matters?. J Allergy Clin Immunol 140: 381-383. https://doi.org/10.1016/j.jaci.2017.03.042
    [40] Zhang B, Weng Z, Sismanopoulos N, et al. (2012) Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol 159: 23-32. https://doi.org/10.1159/000335178
    [41] Nakao A, Nakamura Y, Shibata S (2015) The circadian clock functions as a potent regulator of allergic reaction. Allergy 70: 467-473. https://doi.org/10.1111/all.12596
    [42] Askenase PW (2005) Mast cells and the mediation of T-cell recruitment in arthritis. N Engl J Med 349: 1294. https://doi.org/10.1056/NEJM200309253491319
    [43] Gordon JR, Galli SJ (1990) Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature 346: 274-276. https://doi.org/10.1038/346274a0
    [44] Zhang B, Alysandratos KD, Angelidou A, et al. (2011) Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol 127: 1522-1531.e8. https://doi.org/10.1016/j.jaci.2011.02.005
    [45] Panula P (2021) Histamine receptors, agonists, and antagonists in health and disease. Handb Clin Neurol 180: 377-387. https://doi.org/10.1016/B978-0-12-820107-7.00023-9
    [46] Ahmad S, Varagic J, Groban L, et al. (2014) Angiotensin (1–12); A chymase mediated cellular angiotensin II substrate. Curr Hypertens Res 16: 429-437. https://doi.org/10.1007/s11906-014-0429-9
    [47] He S, Walls AF (1998) The induction of a prolonged increase in microvascular permeability by human mast cell chymase. Eur J Pharmacol 352: 91-98. https://doi.org/10.1016/S0014-2999(98)00343-4
    [48] Wong CK, Ng SSM, Lun SWM, et al. (2009) Signaling mechanisms regulating the activation of human eosinophils by mast-cell-derived Chymase; implications for mast-cell-eosinophil interaction in allergic inflammation. Immunology 126: 579-587. https://doi.org/10.1111/j.1365-2567.2008.02916.x
    [49] Caughey GH (2007) Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 217: 141-154. https://doi.org/10.1111/j.1600-065X.2007.00509.x
    [50] Saarinen JV, Harvima RJ, Naukkarinen A, et al. (2001) The release of histamine is associated with the inactivation of mast cell chymase during immediate allergic wheal reactions in the skin. Clin Exp Allergy 31: 593-601. https://doi.org/10.1046/j.1365-2222.2001.01030.x
    [51] Guilarte M, Sala-Cunill A, Luengo O, et al. (2017) The mast cell contact and coagulation system connection in anaphylaxis. Front Immunol 8: 846. https://doi.org/10.3389/fimmu.2017.00846
    [52] Proud D, Togias A, Nacleiro RM, et al. (1983) Kinins are generated in vivo following airway challenge of allergic individuals with allergen. J Clin Invest 72: 1678-1685. https://doi.org/10.1172/JCI111127
    [53] Stone SF, Brown SG (2012) Mediators released during human anaphylaxis. Curr Allergy Asthma Rev 12: 33-41. https://doi.org/10.1007/s11882-011-0231-6
    [54] Caughey GH (2016) Mast cell proteases as pharmacological targets. Eur J Pharmacol 778: 44-55. https://doi.org/10.1016/j.ejphar.2015.04.045
    [55] Imamura T, Dubin A, Moore W, et al. (1996) Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 74: 861-870.
    [56] Vadas P, Gold M, Perelman B, et al. (2008) Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 358: 28-35. https://doi.org/10.1056/NEJMoa070030
    [57] Fukuda Y, Kawashima H, Saito K, et al. (2000) Effect of human plasma-type platelet activating factor acetylhydrolase in two anaphylactic shock models. Eur J Pharmacol 390: 203-207. https://doi.org/10.1016/S0014-2999(99)00920-6
    [58] Arimura A, Harada M (1991) Differential effect of a PAF antagonist CV- 3988 on active and passive anaphylactic shock in various mouse strains. Lipids 26: 1386-1390. https://doi.org/10.1007/BF02536572
    [59] Gill P, Jindal NL, Jagdis A, et al. (2015) Platelets in the immune response; Revisiting platelet activating factor in anaphylaxis. J Allergy Clin Immunol 135: 1424-1432. https://doi.org/10.1016/j.jaci.2015.04.019
    [60] Kajiwara N, Sasaki T, Braddind P, et al. (2010) Activation of human mast cells through the platelet-activating factor receptor. J Allergy Clin Immunology 125: 1137-1145. https://doi.org/10.1016/j.jaci.2010.01.056
    [61] Dao VT, Medini S, Bisha M, et al. (2016) Nitric oxide up-regulates endothelial expression of angiotensin II type 2 receptors. Biochem Pharmacol 112: 24-36. https://doi.org/10.1016/j.bcp.2016.05.011
    [62] Mombouli JV, Vanhoutte PM (1992) Heterogeneity of endothelium-dependent vasodilator effects of angiotensin converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 20: S74-S82. https://doi.org/10.1097/00005344-199200209-00014
    [63] Lowenstein CJ, Michel T (2006) What's in a name? eNOS and anaphylactic shock. J Clin Invest 116: 2075-2078. https://doi.org/10.1172/JCI29406
    [64] Kuehn HS, Radinger M, Gilfillan AM (2010) Measuring mast cell mediator release. Curr Protoc Immunol 2 Chapter 7: Unit 7.38. https://doi.org/10.1002/0471142735.im0738s91
    [65] Nguyen SMT, Rupprecht CP, Haque A, et al. (2021) Mechanisms governing anaphylaxis: inflammatory cells, mediators, endothelial gap junctions and beyond. Int J Mol Sci 22: 7785. https://doi.org/10.3390/ijms22157785
    [66] Dileepan KN, Raveendran VV, Sharma R (2023) Mast cell-mediated immune regulation in health and disease. Front Med (Lausanne) 10: 1213320. https://doi.org/10.3389/fmed.2023.1213320
    [67] Mukai K, Tsai M, Saito, et al. (2018) Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev 282: 121-150. https://doi.org/10.1111/imr.12634
    [68] Noordenbos T, Blijdorp I, Chen S, et al. (2016) D. Human mast cells capture, store, and release bioactive, exogenous IL-17A. J Leukoc Biol 100: 453-462. https://doi.org/10.1189/jlb.3HI1215-542R
    [69] Moulin D, Donzé O, Talabot-Ayer D, et al. (2007) Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225. https://doi.org/10.1016/j.cyto.2007.09.013
    [70] Saluja R, Ketelaar ME, Hawro T, et al. (2015) The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 63: 80-85. https://doi.org/10.1016/j.molimm.2014.06.018
    [71] Silver MR, Margulis A, Wood N, et al. (2010) IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 59: 207-218. https://doi.org/10.1007/s00011-009-0088-5
    [72] Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. (2003) IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol 171: 4830-4836. https://doi.org/10.4049/jimmunol.171.9.4830
    [73] Theoharides TC, Zhang B, Kempuraj D, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107: 4448-4453. https://doi.org/10.1073/pnas.1000803107
    [74] Petra AI, Tsilioni I, Taracanova A, et al. (2018) Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy Asthma Proc 39: 153-160. https://doi.org/10.2500/aap.2018.38.4105
    [75] Salamon P, Shoham NG, Gavrieli R, et al. (2005) Human mast cells release Interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 60: 1316-1319. https://doi.org/10.1111/j.1398-9995.2005.00886.x
    [76] Sumpter TL, Ho CH, Pleet AR, et al. (2015) Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. J Allergy Clin Immunol 135: 1019-1030.e8. https://doi.org/10.1016/j.jaci.2014.07.036
    [77] Conti P, Caraffa Al, Kritas SK, et al. (2017) Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues. J Biol Regul Homeost Agents 31: 263-267.
    [78] Bruhns P, Chollet-Martin S (2021) Mechanisms of human drug-induced anaphylaxis. J Allergy Clin Immunol 147: 1133-1142. https://doi.org/10.1016/j.jaci.2021.02.013
    [79] Zhang B, Li Q, Shi C, et al. (2018) Drug-induced pseudoallergy: A review of the causes and mechanisms. Pharmacology 101: 104-110. https://doi.org/10.1159/000479878
    [80] Yu Y, Blokhuis BR, Garssen J, et al. (2016) Non-IgE mediated mast cell activation. Eur J Pharmacol 778: 33-43. https://doi.org/10.1016/j.ejphar.2015.07.017
    [81] Cao J, Papadopoulou N, Kempuraj D, et al. (2005) Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. J Immunol 174: 7665-7675. https://doi.org/10.4049/jimmunol.174.12.7665
    [82] Caceda R, Kinkead B, Nemeroff CB (2006) Neurotensin: role in psychiatric and neurological diseases. Peptides 27: 2385-2404. https://doi.org/10.1016/j.peptides.2006.04.024
    [83] Lazarus LH, Perrin MH, Brown MR, et al. (1977) Verification of both the sequence and conformational specificity of neurotensin in binding to mast cells. Biochem Biophys Res Commun 76: 1079-1085. https://doi.org/10.1016/0006-291X(77)90966-4
    [84] Theoharides TC (2017) Neuroendocrinology of mast cells: challenges and controversies. Exp Dermatol 26: 751-759. https://doi.org/10.1111/exd.13288
    [85] Theoharides TC, Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146: 1-12. https://doi.org/10.1016/j.jneuroim.2003.10.041
    [86] McNeil BD, Pundir P, Meeker S, et al. (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519: 237-241. https://doi.org/10.1038/nature14022
    [87] Kolkhir P, Elieh-Ali-Komi D, Metz M, et al. (2022) Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol 22: 294-308. https://doi.org/10.1038/s41577-021-00622-y
    [88] Yoo HS, Yang EM, Kim MA, et al. (2014) A case of codeine induced anaphylaxis via oral route. Allergy Asthma Immunol Res 6: 95-97. https://doi.org/10.4168/aair.2014.6.1.95
    [89] Casale TB, Bowman S, Kaliner M (1984) Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 73: 775-781. https://doi.org/10.1016/0091-6749(84)90447-0
    [90] Logothetidis S (2014) Nanomedicine and Nanobiotechnology. Berlin, Heidelberg: Springer. Available from: https://doi.org/10.1007/978-3-642-24181-9
    [91] Dézsi L, Fülöp T, Mészáros T, et al. (2014) Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. J Control Release 195: 2-10. https://doi.org/10.1016/j.jconrel.2014.08.009
    [92] Drouin SM, Kildsgaard J, Haviland J, et al. (2001) Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166: 2025-2032. https://doi.org/10.4049/jimmunol.166.3.2025
    [93] Hartmann K, Henz BM, Krüger-Krasagakes S, et al. (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89: 2863-2870. https://doi.org/10.1182/blood.V89.8.2863
    [94] Kanagaratham C, El Ansari YS, Lewis OL, et al. (2020) IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy. Front Immunol 11: 603050. https://doi.org/10.3389/fimmu.2020.603050
    [95] Nimmerjahn F, Bruhns P, Horiuchi K, et al. (2005) Fcgamma RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51. https://doi.org/10.1016/j.immuni.2005.05.010
    [96] Bruhns P, Jonsson F (2015) Mouse and human FcR effector functions. Immunol Rev 268: 25-51. https://doi.org/10.1111/imr.12350
    [97] Nimmerjahn F, Ravetch JV (2008) Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47. https://doi.org/10.1038/nri2206
    [98] Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24: 19-28. https://doi.org/10.1016/j.immuni.2005.11.010
    [99] Cocchiara R, Albeggiani G, Di Trapani G (1990) Modulation of rat peritoneal mast cell and human basophil histamine release by estrogens. Int Arch Allergy Appl Immunol 93: 192-197. https://doi.org/10.1159/000235300
    [100] Nakasato H, Ohrui T, Sekizawa K (1999) Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist. J Allergy Clin Immunol 104: 585-588. https://doi.org/10.1016/S0091-6749(99)70327-1
    [101] Vliagoftis H, Dimitriadou V, Boucher W, et al. (1992) Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 98: 398-409. https://doi.org/10.1159/000236217
    [102] Vrieze A, Postma DS, Kerstjens HA (2003) Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol 112: 271-282. https://doi.org/10.1067/mai.2003.1676
    [103] Zaitsu M, Narita S, Lambert KC, et al. (2007) Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol 44: 1977-1985. https://doi.org/10.1016/j.molimm.2006.09.030
    [104] Howard PJ, Ambrosuis WT, Tewksbury DA, et al. (1998) Serum Angiotensinogen concentration in relation to gonadal hormones, body size and genotype in growing young people. Hypertension 32: 875-879. https://doi.org/10.1161/01.HYP.32.5.875
    [105] Giacchetti G, Faloia E, Mariniello B, et al. (2002) Over expression of the renin angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertension 15: 381-388. https://doi.org/10.1016/S0895-7061(02)02257-4
    [106] Reinholz M, Ruzicka T, Schauber J (2012) Vitamin D and its role in allergic disease. Clin Exp Allergy 42: 817-826. https://doi.org/10.1111/j.1365-2222.2011.03923.x
    [107] Agrawal T, Gupta GK, Agrawal DK (2013) Vitamin D supplementation reduces airway hyperresponsiveness and allergic airway inflammation in a murine model. Clin Exp Allergy 43: 672-683. https://doi.org/10.1111/cea.12102
    [108] Aranow C (2011) Vitamin D and the immune system. J Investig Med 59: 881-886. https://doi.org/10.2310/JIM.0b013e31821b8755
    [109] Hewison M (2010) Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 39: 365-379. https://doi.org/10.1016/j.ecl.2010.02.010
    [110] Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3: 27-41. https://doi.org/10.1038/nrd1283
    [111] Mahon BD, Wittke A, Weaver V, et al. (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89: 922-932. https://doi.org/10.1002/jcb.10580
    [112] Fabri M, Stenger S, Shin DM, et al. (2011) Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3: 104ra102. https://doi.org/10.1126/scitranslmed.3003045
    [113] Gupta A, Dimeloe S, Richards DF, et al. (2014) Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma. Thorax 69: 508-515. https://doi.org/10.1136/thoraxjnl-2013-203421
    [114] Herman K, Ring J (1990) Hymenoptera venom anaphylaxis: may decrease levels of angiotensin peptides play a role?. Clin Exp All 20: 569-570. https://doi.org/10.1111/j.1365-2222.1990.tb03151.x
    [115] Herman K, Ring J (1993) The renin angiotensin system and hymenoptera venom anaphylaxis. Clin Exp Allergy 23: 762-769. https://doi.org/10.1111/j.1365-2222.1993.tb00364.x
    [116] Summers CW, Pumphrey RS, Woods CN, et al. (2008) Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist centre. J Allergy Clin Immunol 121: 632-638. https://doi.org/10.1016/j.jaci.2007.12.003
    [117] Slade CA, Douglass JA (2014) Changing practice: no need to stop ACE inhibitors for venom immunotherapy. Clin Exp Allergy 44: 617-619. https://doi.org/10.1111/cea.12295
    [118] Varney VA, Warner A, Ghosh A, et al. (2012) IgE mediated anaphylaxis to foods, venom, and drugs; influence of serum angiotensin converting enzyme levels and genotype. J Allergy (Cairo) 2012: 258145. https://doi.org/10.1155/2012/258145
    [119] Niedoszytko M, Ratajska M, Jassem E (2007) AGT(M235T), ACE(I/D, I/I, D/D) polymorphism in patients with insect venom allergy preliminary results. Allergy 62: 111.
    [120] Mueller UR (1990) Clinical presentation and pathogenesis. Insect sting allergy . Stuttgart: Gustav Fischer 33-65.
    [121] Dimitropoulou C, Chatterjee A, McCloud L (2006) Angiotensin, bradykinin and the endothelium. The Vascular Endothelium I. Handbook of Experimental Pharmacology . Berlin, Heidelberg: Springer 255-294. https://doi.org/10.1007/3-540-32967-6_8
    [122] Varney VA, Nicholas A, Warner A, et al. (2019) IgE-mediated systemic anaphylaxis and its association with gene polymorphisms of ACE, angiotensinogen and chymase. J Asthma Allergy 12: 343-361. https://doi.org/10.2147/JAA.S213016
    [123] Nisho H, Takai S, Miyazaki M, et al. (2005) Usefulness of serum mast cells specific chymase levels for postmortem diagnosis of anaphylaxis. Int J Legal Med 119: 331-334. https://doi.org/10.1007/s00414-005-0524-1
    [124] Zhou X, Whitworth HS, E-Khedr M, et al. (2011) Mast cell chymase: a useful marker in anaphylaxis. J Allergy Clin Immunol 127: 990-997. https://doi.org/10.1016/j.jaci.2011.01.057
    [125] Gulen T, Akin C (2021) Idiopathic anaphylaxis: a perplexing diagnostic challenge for allergists. Curr Allergy Asthma Rep 21: 11. https://doi.org/10.1007/s11882-021-00988-y
    [126] Akin C (2014) Mast cell activation disorders. J Allergy Clin Immunol Pract 2: 252-257. https://doi.org/10.1016/j.jaip.2014.03.007
    [127] Metcalfe DD, Peavy RD, Gilfillan AM (2009) Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 124: 639-646. https://doi.org/10.1016/j.jaci.2009.08.035
    [128] Gulen T, Hagglund H, Dahlen SE, et al. (2014) Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis. Lancet 383: 1608. https://doi.org/10.1016/S0140-6736(14)60585-7
    [129] Valent P, Akin C, Arock M, et al. (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157: 215-225. https://doi.org/10.1159/000328760
    [130] Nakamura Y, Nakano N, Ishimaru K, et al. (2016) Inhibition of IgE-mediated allergic reactions by pharmacologically targeting the circadian clock. J Allergy Clin Immunol 137: 1226-1235. https://doi.org/10.1016/j.jaci.2015.08.052
    [131] Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. (2014) Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol 89: 493-498. https://doi.org/10.1002/ajh.23672
    [132] Bonadonna P, bonifacio M, Lambarderdo C, et al. (2015) Hymenoptera anaphylaxis and C-KIT Mutations: An unexpected association. Curr Allergy Asthma Rep 15: 49. https://doi.org/10.1007/s11882-015-0550-0
    [133] Sonneck K, Florian S, Mullauer L, et al. (2007) Diagnostic and sub-diagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 142: 158-164. https://doi.org/10.1159/000096442
    [134] Valent P, Akin C, Bonadonna P, et al. (2019) Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract 7: 1125-1133. https://doi.org/10.1016/j.jaip.2019.01.006
    [135] Gulen T, Hagglund H, Dahlen B, et al. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med 279: 211-228. https://doi.org/10.1111/joim.12410
    [136] Valent P, Akin C, Metcalfe DD (2016) Mastocytosis 2016: updated WHO classification and novel emerging treatment concepts. Blood 129: 1420-1427. https://doi.org/10.1182/blood-2016-09-731893
    [137] Gotlib J, Kluin-Nelemans HC, George TI, et al. (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374: 2530-2541. https://doi.org/10.1056/NEJMoa1513098
    [138] Fuchs D, Kilbertus A, Kofler K, et al. (2021) Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. J Allergy Clin Immunol Pract 9: 1705-1712.e4. https://doi.org/10.1016/j.jaip.2020.12.022
    [139] Kennedy VE, Perkins C, Reiter A, et al. (2023) Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry. Blood Adv 7: 1713-1724. https://doi.org/10.1182/bloodadvances.2022008292
    [140] Gulen T, Ljung C, Nilsson G, et al. (2017) Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract 5: 1248-1255. https://doi.org/10.1016/j.jaip.2017.02.008
    [141] Gulen T, Hagglund H, Dahlen B, et al. (2014) High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy 44: 121-129. https://doi.org/10.1111/cea.12225
    [142] Monaco A, Choi D, Uzun S, et al. (2022) Association of mast-cell-related conditions with hypermobile syndromes: a review of the literature. Immunol Res 70: 419-431. https://doi.org/10.1007/s12026-022-09280-1
    [143] Sumantri S, Rengganis I (2023) Immunological dysfunction and mast cell activation syndrome in long COVID. Asia Pac Allergy 13: 50-53. https://doi.org/10.5415/apallergy.0000000000000022
    [144] Voelker D, Pongdee T (2014) Urine mast cell mediators in the evaluation and diagnosis of mast cell activation syndrome. Curr Allergy Asthma Rep 24: 33-38. https://doi.org/10.1007/s11882-024-01128-y
    [145] Zhu L, Jian X, Zhou B, et al. (2024) Gut microbiota facilitate chronic spontaneous urticaria. Nat Commun 15: 112. https://doi.org/10.1038/s41467-023-44373-x
    [146] Robey RC, Wilcock A, Bonin H, et al. (2020) Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression. J Allergy Clin Immunol Pract 8: 3549-3556. https://doi.org/10.1016/j.jaip.2020.05.057
    [147] Chollet MB, Akin C (2021) Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. J Allergy Clin Immunol 148: 889-894. https://doi.org/10.1016/j.jaci.2021.06.017
    [148] Butterfield JH, Ravi A, Pongdee T (2018) Mast cell mediators of significance in clinical practice in mastocytosis. Immunol Allergy Clin North Am 38: 397-410. https://doi.org/10.1016/j.iac.2018.04.011
    [149] Lyons JJ, Sun G, Stone KD, et al. (2014) Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol 133: 1471-1474. https://doi.org/10.1016/j.jaci.2013.11.039
    [150] Lyons JJ, Yu X, Hughes JD, et al. (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 48: 1564-1569. https://doi.org/10.1038/ng.3696
    [151] Simons FE, Ardusso LR, Bilo MB, et al. (2011) World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J 4: 13-37. https://doi.org/10.1097/WOX.0b013e318211496c
    [152] Braganza SC, Acworth JP, McKinnon DR, et al. (2006) Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 91: 159-163. https://doi.org/10.1136/adc.2004.069914
    [153] Muraro A, Roberts G, Worm M, et al. (2014) Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy 69: 1026-1045. https://doi.org/10.1111/all.12437
    [154] Jarkvist J, Salehi C, Akin C, et al. (2020) Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection. Allergy 75: 169-177. https://doi.org/10.1111/all.13980
    [155] Broesby-Olsen S, Vestergaard H, Mortz CG, et al. (2018) Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy 73: 230-238. https://doi.org/10.1111/all.13237
    [156] Gotlib J, Kluin-Nelemans HC, Akin C, et al. (2021) Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther 21: 487-498. https://doi.org/10.1080/14712598.2021.1837109
    [157] Gotlib J, Kluin-Nelemans HC, George TI, et al. (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374: 2530-2541. https://doi.org/10.1056/NEJMoa1513098
    [158] Kudlaty E, Perez M, Stein BL, et al. (2021) Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib. J Allergy Clin Immunol Pract 9: 2534-2536. https://doi.org/10.1016/j.jaip.2021.02.040
  • This article has been cited by:

    1. Jiawei Wang, Yanqin Liu, Limei Yan, Kunling Han, Libo Feng, Runfa Zhang, Fractional sub-equation neural networks (fSENNs) method for exact solutions of space–time fractional partial differential equations, 2025, 35, 1054-1500, 10.1063/5.0259937
  • Reader Comments
  • © 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1883) PDF downloads(97) Cited by(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog